Any current/future new fundraising through debt or equity?

No major capex or new fundraising planned for FY2024 as the company aims to consolidate cash flows and revenue. No current plans for Greenfield or Brownfield expansions, indicating limited immediate need for debt or equity raising. Regular maintenance capex only, suggesting stable capital expenditure without large funding requirements. Any major capex or fundraising may be considered from FY2025 onwards, depending on FY2024 performance. Overall focus is on optimizing existing operations and R&D for margin improvement rather than expansion requiring external funding.

Any current/future capex/capital investment/strategic investment?

No major capex planned for FY2024; focus is on consolidating cash flows and driving revenue growth first. Only regular, normal plant maintenance capex expected in FY2024, nothing extraordinary. No plans for Greenfield or Brownfield expansions currently; company prefers to consolidate operations before new projects. Potential capex may be considered in FY2025 depending on FY2024 performance. R&D investment is focused on cost optimization, backward integration (making intermediates and KSMs in-house), and exploring new therapeutic categories. Increasing capacity utilization (targeting

Future growth expectations in sales/revenue/volumes?

The company expects around **20% topline (revenue) growth** in FY2024 compared to FY2023. Growth drivers include existing businesses, ARV segment revival, anti-diabetic segment, and Ibuprofen volumes. ARV business contribution is anticipated to be around **20%** in coming quarters, marking a recovery from previous low levels. Capacity utilization is targeted to improve to **75-80%** in FY2024, supporting volume growth. Ibuprofen commercial capacity is expanding from **300 MT to 700-900 MT per month** within six months, aiding volume increase. The company aims to consolidate current c

Future growth expectations in earnings/operating earnings/profits/EPS?

SMS Pharmaceuticals is targeting around 20% topline growth in FY2024 compared to FY2023. EBITDA margins are expected to improve towards 17%, with aims to achieve pre-COVID levels of around 20% margin over the next two years. ARV segment EBITDA margin is expected to be around 15%, with a revenue contribution targeted at approximately 20%. The company plans better margin realization through vertical integration, backward integration, and in-house production of key starting materials to optimize costs. Raw material prices have stabilized, which is expected to support margin expansion grad

Current/ Expected Orderbook/ Pending Orders?

The ARV (Antiretroviral) segment has recently added more customers, with orders now starting to flow in. Healthy orders of ARV products are expected for at least the next two to three quarters. The company expects a decent contribution from the ARV segment, targeting around 20% revenue contribution. The operating segment is tender-driven, but SMS Pharmaceuticals is only an API player; formulators bid for tenders. No specific values for the current order book or pending orders are disclosed in the transcript. Overall, the outlook suggests a growing and steady order inflow in key segments like A

SMS Pharmaceuticals LtdQ4 FY23Pharmaceuticals & Biotechnology

SMS Pharmaceuticals Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹479P/E: 43.4Market Cap: ₹4.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Order

Yes

Capex

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company expects around 20% topline (revenue) growth in FY2024 compared to FY2023.
Growth drivers include existing businesses, ARV segment revival, anti-diabetic segment, and Ibuprofen volumes.
ARV business contribution is anticipated to be around 20% in coming quarters, marking a recovery from previous low levels.
Capacity utilization is targeted to improve to 75-80% in FY2024, supporting volume growth.
Ibuprofen commercial capacity is expanding from 300 MT to 700-900 MT per month within six months, aiding volume increase.
The company aims to consolidate current capacities before future expansions, with no major capex planned in FY2024.
Growth is expected to be supported by increased domestic and semi-regulated market presence, particularly for products like alfuzosin.

Margin guidance

Category 1

SMS Pharmaceuticals is targeting around 20% topline growth in FY2024 compared to FY2023.
EBITDA margins are expected to improve towards 17%, with aims to achieve pre-COVID levels of around 20% margin over the next two years.
ARV segment EBITDA margin is expected to be around 15%, with a revenue contribution targeted at approximately 20%.
The company plans better margin realization through vertical integration, backward integration, and in-house production of key starting materials to optimize costs.
Raw material prices have stabilized, which is expected to support margin expansion gradually.
Ibuprofen volumes are expected to grow substantially with capacity increasing from 300 MT to 700-900 MT per month over six months, supporting revenue growth.
Focus on R&D and cost optimization is seen as a key driver to improve operating profitability going forward.

See what SMS Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No major capex or new fundraising planned for FY2024 as the company aims to consolidate cash flows and revenue.
No current plans for Greenfield or Brownfield expansions, indicating limited immediate need for debt or equity raising.
Regular maintenance capex only, suggesting stable capital expenditure without large funding requirements.
Any major capex or fundraising may be considered from FY2025 onwards, depending on FY2024 performance.
Overall focus is on optimizing existing operations and R&D for margin improvement rather than expansion requiring external funding.

Order book

Yes

The ARV (Antiretroviral) segment has recently added more customers, with orders now starting to flow in.
Healthy orders of ARV products are expected for at least the next two to three quarters.
The company expects a decent contribution from the ARV segment, targeting around 20% revenue contribution.
The operating segment is tender-driven, but SMS Pharmaceuticals is only an API player; formulators bid for tenders.
No specific values for the current order book or pending orders are disclosed in the transcript.
Overall, the outlook suggests a growing and steady order inflow in key segments like ARV for FY2024.

See what SMS Pharmaceuticals Ltd management said on order book — free account, 30 seconds.

Capex plans

No major capex planned for FY2024; focus is on consolidating cash flows and driving revenue growth first.
Only regular, normal plant maintenance capex expected in FY2024, nothing extraordinary.
No plans for Greenfield or Brownfield expansions currently; company prefers to consolidate operations before new projects.
Potential capex may be considered in FY2025 depending on FY2024 performance.
R&D investment is focused on cost optimization, backward integration (making intermediates and KSMs in-house), and exploring new therapeutic categories.
Increasing capacity utilization (targeting 75-80% for FY2024) before pursuing any capacity expansions.

Track SMS Pharmaceuticals Ltd — get its next earnings analysis in your feed

How does SMS Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSMS Pharmaceuticals Ltd

Rev 2Mar 1

See where SMS Pharmaceuticals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does SMS Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Compare SMS Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What SMS Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →